Balboa Biosciences is committed to the development and commercialization of proprietary product candidates for the treatment of Central Nervous System disorders and acute and chronic Pain.

Balboa Biosciences currently has 3 products in clinical development:

BB 103
- Fast-to-Market product for acute and chronic pain

BB 102
- A novel neuroprotective agent with multiple indication potential

BB 101
- A new agent in development for treatment for acute and chronic pain